Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT02482363 |
| Other study ID # |
170108 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
September 1, 2015 |
| Est. completion date |
March 31, 2016 |
Study information
| Verified date |
May 2024 |
| Source |
University of Edinburgh |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Season of birth influences pregnancy for reasons that remain unclear however the answer may
lie in the amount of sunshine pregnant women are exposed to. Sunshine, or ultraviolet light
(UV) exposure is already known to have benefits for health on heart disease, strokes and
depression. In pregnancy, relationships between sunshine exposure are evident in birth
weight, preterm birth and risk of blood pressure complications. Vitamin D, the UV generated
hormone, was thought to be responsible when low vitamin D levels were associated with these
pregnancy complications. However, vitamin D replacement is ineffective at preventing these
outcomes, and the investigators hypothesise that this is because it is the UV that is
beneficial for pregnancy and it is working through a different pathway.
A new understanding of skin function is central to this, with a 2014 study showing that
exposing an adult to 20 minutes of low dose UV light lowered their blood pressure and
improved blood flow. These investigators demonstrated this was a direct effect of UV on the
skin and was mediated by nitric oxide, a chemical central to many aspects of pregnancy
including blood pressure regulation and uterine activity.
The investigators in this study have funding from Tommy's to investigate if a similar effect
is seen in pregnancy on the circulation. The design is similar to the previously successful
method and volunteers would be recruited from clinical areas during the second trimester. As
both resting and warming for 20 minutes have the potential to have similar effects on the
circulation, a control arm will expose participants to these without the UV.
This pilot study would involve one visit and measurements taken would include heart rate,
blood pressure, arteriography, ultrasound of the uterine arteries and blood measurements of
nitric oxide levels. Arteriography is performed using a specialised arm cuff and is safe and
non-invasive. A subset of these women would be invited to repeat this in the third trimester
to investigate for a difference in effect at a later gestation.
Description:
The hypothesis is that ultraviolet A (UVA) exposure during pregnancy will release nitric
oxide (NO) from the skin and that in turn this will cause blood vessel dilatation. This will
be seen by changes in uterine artery blood flow, blood pressure, and arterial stiffness
(arteriography). The aim is to investigate this in a low risk group and a high risk group, as
these 2 groups of women have different baseline characteristics of their vascular system and
potentially different responses to our intervention. A subset of these women will be invited
to repeat the intervention in the third trimesters of their pregnancies to establish if the
effect differs with advancing gestation. Birth outcomes on participants will be collected to
check if the high and low risk groups are representative of this status.
Participant contact information will be kept separately from their collected data to
anonymise the collected data and all outcome data will be de-identified. All collected
information will be stored on secure university servers that are password protected.
Participants will be recruited to participate in the low sunshine months November 1st until
March 1st to minimise background sunshine and UV exposure.
LOW RISK ARM:
20 participants will be recruited from community and hospital antenatal clinics, day
assessment unit, labour ward or at first trimester screen appointment by posters, a research
midwife or a member of clinical research team. Potential participants will be given an
information form and will be asked to give written consent following sufficient time for
consideration.
The participants will be between 14 and 28 weeks pregnant at the time of the intervention and
have no pregnancy related complications or risk factors for pre-eclampsia or growth
restriction.
Over a single morning or afternoon the protocol will be completed with the participant
exposed to both the intervention and the control in the one 4 hour period. The intervention
participants will be exposed to is ultraviolet A for 20minutes in a dermatology phototherapy
cabinet. This is the equivalent of 2 standard erythemal doses (SED's) of UV light exposure.
On a normal summer day in Northern Europe the general population would expect to receive
30-40 SED's. In the control intervention participants will be exposed to sham irradiation
where they will undergo this exposure while wearing a loose fitting paper boiler suit that is
UVA impenetrable to prevent UVA exposure. Protective sunglasses will be provided.
On arrival at the Wellcome Trust Clinical Research Facility, participants will be randomized
to the active or control treatment arm first with a simple randomisation method (coin toss)
by a member of the clinical research team. As the groups will be controlled for risk factors,
the main important covariate is age. The purpose of randomisation in this setting is to aid
with blinding the ultrasound investigator to which arm the patient is in, as the investigator
can affect ultrasound results. As such, a simple randomisation procedure such as a coin toss
by the research nurse on arrival is appropriate. One toss will determine group allocation
with heads getting control exposure first and tails getting intervention first. This will be
recorded on the participant information sheet and unblinded for analysis. The participant
will then rest seated for 30 minutes in comfortable clothing in a temperature controlled room
at 25 degrees Celsius. They will be assigned a study number and the researcher will collect
pregnancy and maternal characteristics.
A member of the research team will measure baseline blood pressure, skin temperature, heart
rate and perform arteriography. Arteriography has a standard collecting procedure and is an
established tool to measure stiffness of the aorta (the largest blood vessel from the heart).
An ultrasound will confirm fetal viability and baseline uterine artery Doppler measurements.
An intravenous (IV) cannula will be inserted and a 5ml venous blood sample will be collected
by an experienced member of the clinical research team.
The participant will then be exposed to the intervention of UVA for 20 minutes in either
their underwear (active) or in a loose fitting paper boiler suit that is UVA impenetrable.
The suit allows the skin to heat up, but not be exposed to the UVA. This controls for any
temperature effects. The investigator performing ultrasound is blinded to whether the
participant was wearing the suit or not by the use of a research nurse and the investigator
not being present during the irradiation.
Immediately following exposure BP, heart rate, skin temperature and uterine artery Doppler's
will be measured at 10 minutely intervals for 1 hour. 3 measurements will be collected at
each time point for BP, heart rate and uterine artery Doppler. A venous blood sample will be
collected from the cannula at the 0, 30 and 60 minute time points. At the 60 minute time
point, arteriography will be repeated. Uterine artery Doppler images will be stored with a
study number for offline analysis.
The participant will then cross over in to the other arm, which the investigator remains
blind to and the process is repeated.
HIGH RISK ARM:
20 participants between 14 and 28 weeks will be referred from their direct care team based on
historical risk factors in a previous pregnancy or high risk factors in their current
pregnancy including essential hypertension, renal or vascular disease, previous intrauterine
growth restriction or from a low Papp-A result on their first trimester screening blood
tests. Papp-A is measured as part of first trimester screening and is produced by the
developing placenta. Low results are associated with poor fetal growth and pre-eclampsia.
Their direct care team in community or hospital antenatal clinics, day assessment unit or in
the ultrasound department may identify these potential participants and refer them to the
research team if they are interested in participating. This will include midwives, doctors
and ultrasound staff. A poster and mechanism for self referral will be present in the care
areas of antenatal clinic and the ultrasound department. If they give consent, they will be
recruited to participate. If there is any concerns about fetal or maternal well being they
will be excluded from this trial.
They will undergo the above protocol including randomisation.
LONGITUDINAL ARM:
All participants will be invited to return to undergo the trial protocol again at a third
trimester time point within the 3 month window that the trial is being run. The investigators
would aim to collect 10 from the low risk group and 10 from the high risk group. Participants
whose third trimester commences outside this window will not be eligible for the longitudinal
group.
FOR ALL GROUPS:
The consent will include permission to collect birth outcomes once they are delivered.
Outcomes of interest will be pregnancy outcome (stillbirth, live birth), birth weight,
gestational length, incidence of pre-eclampsia or pregnancy induced hypertension. This will
be retrieved from the medical record and will be used for post hoc subgroup analysis to
assess for any difference in response to UVA exposure. The study will conclude once the last
baby is delivered and their birth data collected.
Results will be recorded in an anonymised way with a study number, and anonymised data will
be stored separately to participant data. After the last pregnancy is delivered, all data
will be completely de-identified. Blood samples will be stored in the Edinburgh Reproductive
Tissue Biobank with participant consent.
